Progressive Supranuclear Palsy: Pathology and Genetics

Overview

Journal Brain Pathol

Date 2007 May 12

PMID 17493041

Citations 112

Authors

Dennis W Dickson

Rosa Rademakers

Michael L Hutton

Affiliations

Soon will be listed here.

Abstract

Progressive supranuclear palsy (PSP) is an atypical Parkinsonian disorder associated with progressive axial rigidity, vertical gaze palsy, dysarthria and dysphagia. Neuropathologically, the subthalamic nucleus and brainstem, especially the midbrain tectum and the superior cerebellar peduncle, show atrophy. The substantia nigra shows loss of pigment corresponding to nigrostriatal dopaminergic degeneration. Microscopic findings include neuronal loss, gliosis and neurofibrillary tangles in basal ganglia, diencephalon and brainstem. Characteristic tau pathology is also found in glia. The major genetic risk factor for sporadic PSP is a common variant in the gene encoding microtubule-associated protein tau (MAPT) and recent studies have suggested that this may result in the altered expression of specific tau protein isoforms. Imaging studies suggest that there may be sensitive and specific means to differentiate PSP from other parkinsonian disorders, but identification of a diagnostic biomarker is still elusive.

Citing Articles

Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies.

Morderer D, Wren M, Liu F, Kouri N, Maistrenko A, Khalil B Mol Neurodegener. 2025; 20(1):32.

PMID: 40082954 PMC: 11905455. DOI: 10.1186/s13024-025-00817-0.

Single-cell transcriptomic and neuropathologic analysis reveals dysregulation of the integrated stress response in progressive supranuclear palsy.

Whitney K, Song W, Sharma A, Dangoor D, Farrell K, Krassner M Acta Neuropathol. 2024; 148(1):80.

PMID: 39648200 PMC: 11625691. DOI: 10.1007/s00401-024-02823-w.

Cognitive impairment in Parkinson's disease and other parkinsonian syndromes.

Giannakis A, Sioka C, Kloufetou E, Konitsiotis S J Neural Transm (Vienna). 2024; 132(3):341-355.

PMID: 39614911 DOI: 10.1007/s00702-024-02865-0.

Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies.

Slemann L, Gnorich J, Hummel S, Bartos L, Klaus C, Kling A Acta Neuropathol. 2024; 148(1):70.

PMID: 39580770 PMC: 11586312. DOI: 10.1007/s00401-024-02834-7.

Pathologically Confirmed Alzheimer's Disease Presenting as Clinical Parkinson's Disease, A Case Report.

Mohammadzadeh N, Wu C, Donahue J, Friedman J Mov Disord Clin Pract. 2024; 11(9):1141-1144.

PMID: 39367741 PMC: 11452794. DOI: 10.1002/mdc3.14149.

References

Kikuchi H, Doh-ura K, Kira J, Iwaki T . Preferential neurodegeneration in the cervical spinal cord of progressive supranuclear palsy. Acta Neuropathol. 1999; 97(6):577-84. DOI: 10.1007/s004010051033. View

Stanford P, Halliday G, Brooks W, Kwok J, Storey C, Creasey H . Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain. 2000; 123 ( Pt 5):880-93. DOI: 10.1093/brain/123.5.880. View

Poorkaj P, Bird T, Wijsman E, Nemens E, Garruto R, Anderson L . Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998; 43(6):815-25. DOI: 10.1002/ana.410430617. View

Morris H, Osaki Y, Holton J, Lees A, Wood N, Revesz T . Tau exon 10 +16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. Neurology. 2003; 61(1):102-4. DOI: 10.1212/01.wnl.0000072325.27824.a5. View

Myers A, Pittman A, Zhao A, Rohrer K, Kaleem M, Marlowe L . The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2006; 25(3):561-70. DOI: 10.1016/j.nbd.2006.10.018. View

Colosimo C, Osaki Y, Vanacore N, Lees A . Lack of association between progressive supranuclear palsy and arterial hypertension: a clinicopathological study. Mov Disord. 2003; 18(6):694-7. DOI: 10.1002/mds.10392. View

Casseron W, Azulay J, Guedj E, Gastaut J, Pouget J . Familial autosomal dominant cortico-basal degeneration with the P301S mutation in the tau gene: an example of phenotype variability. J Neurol. 2005; 252(12):1546-8. DOI: 10.1007/s00415-005-0880-2. View

Cruts M, Rademakers R, Gijselinck I, van der Zee J, Dermaut B, De Pooter T . Genomic architecture of human 17q21 linked to frontotemporal dementia uncovers a highly homologous family of low-copy repeats in the tau region. Hum Mol Genet. 2005; 14(13):1753-62. DOI: 10.1093/hmg/ddi182. View

Rojo A, Pernaute R, Fontan A, Ruiz P, Honnorat J, Lynch T . Clinical genetics of familial progressive supranuclear palsy. Brain. 1999; 122 ( Pt 7):1233-45. DOI: 10.1093/brain/122.7.1233. View

10.

Paviour D, Price S, Jahanshahi M, Lees A, Fox N . Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain. 2006; 129(Pt 4):1040-9. DOI: 10.1093/brain/awl021. View

11.

Rademakers R, Cruts M, Van Broeckhoven C . The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat. 2004; 24(4):277-95. DOI: 10.1002/humu.20086. View

12.

Rajput A, Dickson D, Robinson C, Ross O, Dachsel J, Lincoln S . Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology. 2006; 67(8):1506-8. DOI: 10.1212/01.wnl.0000240220.33950.0c. View

13.

Ghika J, Bogousslavsky J . Presymptomatic hypertension is a major feature in the diagnosis of progressive supranuclear palsy. Arch Neurol. 1997; 54(9):1104-8. DOI: 10.1001/archneur.1997.00550210038010. View

14.

Steele J, Richardson J, Olszewski J . PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol. 1964; 10:333-59. DOI: 10.1001/archneur.1964.00460160003001. View

15.

Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J . Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999; 8(4):711-5. DOI: 10.1093/hmg/8.4.711. View

16.

Arai H, Morikawa Y, Higuchi M, Matsui T, Clark C, Miura M . Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997; 236(2):262-4. DOI: 10.1006/bbrc.1997.6908. View

17.

Bergeron C, Davis A, Lang A . Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. Brain Pathol. 1998; 8(2):355-65. PMC: 8098360. DOI: 10.1111/j.1750-3639.1998.tb00159.x. View

18.

Morris H, Janssen J, Bandmann O, Daniel S, Rossor M, Lees A . The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 1999; 66(5):665-7. PMC: 1736363. DOI: 10.1136/jnnp.66.5.665. View

19.

Togo T, Sahara N, Yen S, Cookson N, Ishizawa T, Hutton M . Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol. 2002; 61(6):547-56. DOI: 10.1093/jnen/61.6.547. View

20.

Josephs K, Dickson D . Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord. 2003; 18(9):1018-26. DOI: 10.1002/mds.10488. View